(Q37255016)

19 August 2017

1 reference

title

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science (English)

1 reference

19 August 2017

O Kilpivaara

1

1 reference

PubMed ID

18754026

19 August 2017

R L Levine

series ordinal

2

1 reference

19 August 2017

28 August 2008

1 reference

19 August 2017

1 reference

19 August 2017

22

1 reference

19 August 2017

1813-1817

1 reference

19 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/leu.2008.229

19 August 2017

0 references

cites work

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Clonal origin of chronic myelocytic leukemia in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Polycythemia vera: stem-cell and probable clonal origin of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Expression of Bcl-x in erythroid precursors from patients with polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

SNP array karyotyping allows for the detection of uniparental disomy and cryptic chromosomal abnormalities in MDS/MPD-U and MPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Mutational analysis of the tyrosine kinome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Characterization of murine JAK2V617F-positive myeloproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

Clonality in chronic myeloproliferative disorders defined by X-chromosome linked probes: demonstration of heterogeneity in lineage involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

Clonal analysis of haemopoietic cells in essential thrombocythaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

Endogenous Erythroid Colony Formation by Peripheral Blood Mononuclear Cells from Patients with Myelofibrosis and Polycythemia Vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.229

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.229

1 reference

19 August 2017

1 reference

PubMed ID

18754026